(Q39255478)

English

Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maroulio Talieri

object named as

Maroulio Talieri

2

0 references

Andreas Scorilas

object named as

Andreas Scorilas

3

0 references

author name string

Georgia Papachristopoulou

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

publication date

20 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

369-378

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Genomic signatures to guide the use of chemotherapeutics.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Human tissue kallikreins: the cancer biomarker family

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Kallikrein-related peptidases

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Functional roles of human kallikrein-related peptidases

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Human tissue kallikrein gene family: applications in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Telling cells how to die: docetaxel therapy in cancer cell lines.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Cell-growth quantitation methods for the evaluation of antiestrogens in human breast cancer cells in culture

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Analyzing real-time PCR data by the comparative C(T) method

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Prognostic value and biological role of the kallikrein-related peptidases in human malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

The emerging roles of human tissue kallikreins in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

The Feasibility of Enzyme Targeted Activation for Amino Acid/Dipeptide Monoester Prodrugs of Floxuridine; Cathepsin D as a Potential Targeted Enzyme

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0558-1

21 January 2018

Evaluation of kallikrein-related peptidase 5 expression and its significance for breast cancer patients: association with kallikrein-related peptidase 7 expression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression analysis and study of KLK4 in benign and malignant breast tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human tissue kallikreins: physiologic roles and applications in cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Using kallikrein-related peptidases (KLK) as novel cancer biomarkers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23086576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13277-012-0558-1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39255478&oldid=2202727053"